Anticoagulation Monitoring During ECMO Support: Monitor or Flip a Coin?
2024
Anticoagulation Monitoring During ECMO Support: Monitor or Flip a Coin?
Editorial
Evidence: low
Author Information
Author(s): Sasa Rajsic, Benedikt Treml
Primary Institution: Medical University Innsbruck
Conclusion
Monitoring anticoagulation in ECMO patients is crucial, and while anti-factor Xa activity shows moderate correlation with UFH infusion rates, careful clinical decision-making is essential to avoid complications.
Supporting Evidence
- The use of anti-factor Xa activity for monitoring shows moderate correlation with UFH infusion rates.
- ACT is now considered a historical test for anticoagulation monitoring during ECMO.
- The evidence regarding ACT's association with hemostatic complications remains controversial and limited.
- aPTT remains the standard monitoring tool for ECMO patients, but strong evidence for specific thresholds is lacking.
- Anti-factor Xa assays are gaining popularity but require further research to confirm their effectiveness.
Takeaway
Doctors need to check blood thinning levels in patients on ECMO to prevent clots or bleeding, and using certain tests can help, but they need to be careful.
Limitations
The evidence on anticoagulation monitoring in ECMO patients is weak, and many studies are retrospective with high heterogeneity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website